Seasonal changes of proapoptotic soluble Fas ligand level in allergic rhinitis combined with asthma

Pediatric Allergy and Immunology

Volumn 17, Issue 6, 2006, Pages 444-449

  Mezei, Györgyi ^a   Lévay, Magdolna ^a   Sepler, Zsuzsanna ^a   Héninger, Erika ^b   Kozma, Gergely Tibor ^b   Cserháti, Endre ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Allergic rhinitis with or without asthma; Apoptosis; Children; Soluble Fas; Soluble Fas ligand

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; APOPTOSIS; ARTICLE; ASTHMA; BLOOD LEVEL; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; INFLAMMATION; MALE; PATHOGENESIS; POLLEN ALLERGY; PRESCHOOL CHILD; PRIORITY JOURNAL; RAGWEED POLLEN; RESPIRATORY TRACT ALLERGY; SCHOOL CHILD; SEASONAL VARIATION; SYMPTOMATOLOGY;

AMBROSIA; APOPTOSIS; ASTHMA; CHILD; EOSINOPHILS; FAS LIGAND PROTEIN; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULIN E; MALE; MEMBRANE GLYCOPROTEINS; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SEASONS; TUMOR NECROSIS FACTORS;

EID: 33747881130     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2006.00415.x     Document Type: Article

References (22)

1. WEDI B, RAAP U, LEWRICK H, KAPP A. Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J Allergy Clin Immunol 1997: 100: 536-43.
2. VIGNOLA AM, CHANEZ P, CHIAPPARA G, et al. Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J Allergy Clin Immunol 1999: 103: 563-73.
3. MATSUMOTO K, SCHLEIMER RP, SAITO H, IIKURA Y, BOCHNER BS. Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 1995: 86: 1437-43.
4. TSUYUKI S, BERTRAND C, ERARD F, et al. Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. J Clin Invest 1995: 96: 2924-31.
5. OHTA K, YAMASHITA N, TAJIMA M, et al. In vivo effects of apoptosis in asthma examined by a murine model. Int Arch Allergy Immunol 2001: 124: 259-61.
6. DUEZ C, TOMKINSON A, SHULTZ LD, BRATTON DL, GELFAND EW. Fas deficiency delays the resolution of airway hyperresponsiveness after allergen sensitization and challenge. J Allergy Clin Immunol 2001: 108: 547-56.
7. DE ROSE V, CAPPELLO P, SORBELLO V, et al. IFN-gamma inhibits the proliferation of allergen-activated T lymphocytes from atopic, asthmatic patients by inducing Fas/FasL-mediated apoptosis. J Leukoc Biol 2004: 76: 423-32.
8. ZHANG X, BRUNNER T, CARTER L, et al. Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1997: 185: 1837-49.
9. AKDIS M, TRAUTMANN A, KLUNKER S, et al. T helper (Th)2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells. FASEB J 2003: 17: 1026-35.
10. CHENG J, ZHOU T, LIU C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994: 263: 1759-62.
11. CASCINO I, FIUCCI G, PAPO G, RUBERTI G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995: 154: 2706-13.
12. NAGATA S. Apoptosis by death factor. Cell 1997: 88: 355-65 [review].
13. SUDA T, HASHIMOTO H, TANAKA M, OCHI T, NAGATA S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997: 186: 2045-50.
14. SPINOZZI F, FIZZOTTI M, AGEA E, et al. Defective expression of Fas messenger RNA and Fas receptor on pulmonary T cells from patients with asthma. Ann Intern Med 1998: 128: 363-9.
15. SPINOZZI F, AGEA E, FIZZOTTI M, et al. Role of T-helper type 2 cytokines in down-modulation of Fas mRNA and receptor on the surface of activated CD4(+) T cells: molecular basis for the persistence of the allergic immune response. FASEB J 1998: 12: 1747-53.
16. SPINOZZI F. Onset and persistence of the allergic inflammation: a molecular explanation? Arch Immunol Ther Exp (Warsz) 1998: 46: 277-84.
17. JAYARAMAN S, CASTRO M, O'SULLIVAN M, BRAGDON MJ, HOLTZMAN MJ. Resistance to Fas-mediated T cell apoptosis in asthma. J Immunol 1999: 162: 1717-22.
18. KRUG N, TSCHERNIG T, BALKE K, et al. Enhanced expression of Fas ligand (CD95L) on T cells after segmental allergen provocation in asthma. J Allergy Clin Immunol 1999: 103: 649-55.
19. NOMA T, SUGAWARA Y, AOKI K, KAWANO Y, ISHIKAWA Y, MATSUURA N. Induction of peripheral mononuclear cell apoptosis in asthmatic patients in remission. J Asthma 2002: 39: 591-601.
20. ZAKRZEWSKA A, KOBOS J, GRYCZYNSKA D. Evaluation of CD25, CD152, Fas-ligand expression in the adenoids of allergic and non-allergic children: a pilot study. Int J Pediatr Otorhinolaryngol 2003: 67 (Suppl. 1): S205-8.
21. KATO M, HATTORI T, ITO H, et al. Serum-soluble Fas levels as a marker to distinguish allergic and nonallergic rhinitis. J Allergy Clin Immunol 1999: 103: 1213-4.
22. KATO M, NOZAKI Y, YOSHIMOTO T, et al. Different serum soluble Fas levels in patients with allergic rhinitis and bronchial asthma. Allergy 1999: 54: 1299-302.